<DOC>
	<DOCNO>NCT01542489</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial evaluate effect Levemir® ( insulin detemir ) glycaemic control , weight incidence hypoglycaemic event insulin treat subject type 1 type 2 diabetes .</brief_summary>
	<brief_title>Observational Study Predictability Levemir® Terms Metabolic Control , Change Body Weight Hypos</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Any subject type 1 type 2 diabetes treat insulin discretion participate physician decide switch insulin treatment longacting insulin analogue insulin detemir ( Levemir® ) combination either insulin aspart ( NovoRapid® ) human insulin ( Actrapid® )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>